Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0611 • ACR Convergence 2024
Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study
Arthur Mageau¹, Marie-Paule Chauveheid², Chrystelle Francois², Thomas Papo¹ and Karim Sacré¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the…
Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Anca Askanase¹, Edward Vital², Oliver Meier³, Armando Turchetta⁴, Huiyan (Ashley) Mao⁴, Justine Maller⁵, Jorge A. Ross Terres⁶ and Maria Dall'Era⁷, ¹Columbia University Medical Center, New York, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc,, San Francisco, CA, ⁶Genentech, Inc,, San Francisco, ⁷UCSF, Corte Madera, CA
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos², Jasneet Singh², Ingrid Lazaridou², Markos Kalligeros², Eleftherios Mylonakis³ and Anthony M. Reginato⁴, ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, RI, ³Department of Medicine, Houston Methodist Hospital, Houston, ⁴Brown University, Providence, RI
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 0816 • ACR Convergence 2024
Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus
James Ward¹, Mythri Ambatipudi², Zerai Manna³, Michael Smith⁴, Melissa de los Reyes⁵, Adam Schiffenbauer⁶, Saifur Rahman⁷, Kamelia Zerrouki⁵, Fredrick Miller¹, Mariana Kaplan⁸, Jian-Liang Li¹, Kerry Casey⁹, Lisa Rider¹⁰ and Sarfaraz Hasni⁶, ¹National Institute of Environmental Health Sciences, NIH, Durham, NC, ²Harvard Medical School, Boston, MA, ³NIH, Bethesda, MD, ⁴Horizon Therapeutics, Alexandria, VA, ⁵AstraZeneca, Gaithersburg, MD, ⁶NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁷AstraZeneca, Gaithersburg, ⁸NIAMS/NIH, Bethesda, MD, ⁹Regeneron Pharmaceuticals, Terrytown, NY, ¹⁰NIEHS, NIH, Garrett Park, MD
Background/Purpose: Systemic lupus erythematosus (SLE) and dermatomyositis (DM) are hypothesized to be triggered by shared genetic and environmental factors leading to aberrant activation of innate…
Abstract Number: 0997 • ACR Convergence 2024
Geographic and Lifestyle Exposures in Systemic Lupus Erythematosus
Zoe Reed¹, Janis Campbell², Xana Howard¹, Teresa Aberle¹, Bridget Parrish¹, Wade DeJager³, Cristina Arriens¹, Joan Merrill⁴ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) has a complex etiology with genetic predispositions interacting with environmental factors. Extensive environmental exposure information is now publicly available based…
Abstract Number: 1240 • ACR Convergence 2024
Living with Antiphospholipid Antibodies: A Photovoice Exploration
Francesca Cardwell¹, Susan J. Elliott², Paul S. Gibson³, Nancy Soliman⁴, Leslie Skeith⁴, Ann E. Clarke⁵ and Megan Barber⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of Calgary, Calgary, ON, Canada, ⁵Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: The diverse manifestations of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPLs) exert substantial but poorly understood impacts on the lives of those affected. This…
Abstract Number: 1278 • ACR Convergence 2024
The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study
Hunter Hogarth¹, Jida Jaffan¹, Tala El Tal², Oscar Mwizerwa¹, Asha Jeyanathan¹, Ibrahim Mohamed³, Lawrence Ng⁴, Paris Moaf⁵, Joanna Law⁵, Louise Boulard⁶, Ashley Danguecan⁷, Adrienne Davis⁸, Linda Hiraki⁴, Deborah Levy⁴ and Andrea Knight⁹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ²The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁸Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Fatigue is a prevalent and distressing symptom in childhood-onset systemic lupus erythematosus (cSLE), affecting up to 74% of patients with potential for adverse effects…
Abstract Number: 1493 • ACR Convergence 2024
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Jorge Guerra Sayre¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
Abstract Number: 1510 • ACR Convergence 2024
Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Nidia Meras⁸, Cintia Otaduy⁹, Elisa Novatti¹⁰, Valeria Arturi¹¹, Erika S. Palacios Santillan⁷, Boris Kisluk¹², Luciana González Lucero¹³, Eduardo Kerzberg¹⁴, Nicolás Pérez¹⁵, Cecilia Pisoni¹⁶, Paola Pirruccio¹⁷, María E. Crespo¹⁸, Ana Carolina Montandon¹⁹, Andrese A. Gasparin²⁰, Angela Duarte²¹, Laissa C. Alves Alvino²², Eloisa Bonfa²³, Emily Figuereido Neves²⁴, Lucas Victoria De Oliveira Martins²⁵, Iris Guerra²⁶, Milena Mimica Davet²⁷, Lizeth De La Hoz Rueda²⁸, Andrés Cadena Bonfanti²⁸, Roberth Rivera²⁹, Paola Coral Alvarado³⁰, John Fredy Jaramillo³¹, José Martínez³², Mario Moreno³³, Reyna E. Sánchez Briones³⁴, Mario Pérez Cristóbal³⁵, Eduardo Martin Nares³⁶, Yaneli Juárez-Vicuña³⁷, Yelitza González Bello³⁸, Octavio González³⁹, Leonardo R. Aguilar Rivera⁴⁰, Margarita Duarte⁴¹, Patricia Langjarth⁴², Wilkerson Pérez Medina⁴¹, Armando Calvo⁴³, Teresandris Polanco⁴⁴, Carina Pizzarossa⁴⁵, Gonzalo Silveira⁴⁶, Cristina Reategui⁴⁷, Graciela Alarcon⁴⁸, Urbano Sbarigia⁴⁹, Federico Zazzetti⁵⁰, Ashley Orillion⁵¹, Guillermo Pons-Estel⁵² and Bernardo Pons-Estel⁵², ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Córdoba, Córdoba, Spain, ⁹Hospital Córdoba, Cordoba, Spain, ¹⁰Hospital Privado Universitario de Córdoba, Córdoba, Spain, ¹¹Hospital HIGA San Martín, La Plata, Argentina, ¹²Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, ¹³Hospital Padilla, Tucumán, Argentina, ¹⁴Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹⁵Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ¹⁶CEMIC, Buenos Aires, Argentina, ¹⁷Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, ¹⁸Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ²⁰Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²¹Universidad Federal de Pernambuco, Pernambuco, Brazil, ²²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ²³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁴Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Sección de Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ²⁸Universidad Simon Bolivar, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³⁷Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, CDMX, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, Mexico, ⁴⁰Servicio de Reumatología (CEAR). Hospital Universitario "Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico, ⁴¹Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Cayetano Heredia, San Martin de Porres, Peru, ⁴⁴Hospital Docente Padre Billini, Santo Domingo, Dominica, ⁴⁵Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁶Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁷Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁸The University of Alabama at Birmingham, Birmingham, AL, ⁴⁹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵⁰Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵¹Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: To evaluate health-related quality of life (HRQoL) in patients with active lupus nephritis (LN) at baseline and 12 months after treatment in relationship to…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 1547 • ACR Convergence 2024
Hydroxychloroquine and Prednisone Use by Individuals Diagnosed with Systemic Lupus Erythematosus in the TriNetX Research Database
Moises Narvaez¹, Mujeeb Basit² and David Karp³, ¹UT Southwestern Medicial Center, Dallas, ²UT Southwestern Medical Center, Dallas, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The current treatment guidelines for systemic lupus erythematosus emphasize the universal use of antimalarials such as hydroxychloroquine (HCQ) unless contraindicated as well as limited…
Abstract Number: 1685 • ACR Convergence 2024
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Minal Aundhia¹, Jinqi Liu², Ellen Cody³, James Rose⁴, Angela Merritt¹, Megan Quinlan-Waters¹, Alyssa Sproles⁵, Sherry Thornton⁵, Prasad Devarajan⁴, Bin Huang⁶ and hermine brunner⁷, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Bristol Myers Squibb, Princeton, NJ, ³Children's Wisconsin, Milwaukee, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Lupus Nephritis (LN) confers a poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We…
Abstract Number: 1764 • ACR Convergence 2024
Reduction in Circulating Neutrophil Extracellular Traps and Restored Degradation Post-treatment in Pediatric Lupus
Tatiana Borja¹, Bharati Matta², Lydia Thomas³, Jenna Battaglia⁴, Amanda Huang⁵, Kim Simpfendorfer⁶, Hongxiu Wen⁵, Joyce Hui-Yuen⁷, Boris Reizis⁸, Sohei Makita⁸ and Betsy Barnes⁵, ¹Northwell- Cohen Children's Medical Center, Elmhurst, NY, ²The Feinstein Institutes for Medical Research, Manhasset, NY, ³Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ⁴Feinstein Institutes for Medical Science, Manhasset, ⁵Feinstein Institutes for Medical Science, Manhasset, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Northwell Health, Cohen Children's Medical Center, Great Neck, NY, ⁸New York University Grossman School of Medicine, New York, NY
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic, chronic, autoimmune disease in which over 50% of pSLE patients develop lupus nephritis (pLN). Neutrophil extracellular traps (NETs)…
Abstract Number: 1798 • ACR Convergence 2024
CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis
Philip Carlucci¹, Nalani Sachan², Andrea Fava³, Brooke Cohen², Jasmine Shwetar⁴, Siddarth Gurajala⁵, Qian Xiao⁵, Joseph Mears⁶, Katie Preisinger², Devyn Zaminski⁷, Kristina Deonaraine⁸, Peter Izmirly⁹, Judith James¹⁰, Joel Guthridge¹⁰, Wade DeJager¹¹, David Wofsy¹², Cynthia Loomis², Gyles Ward², Ming Wu¹³, Chaim Putterman¹⁴, Deepak Rao¹⁵, Betty Diamond¹⁶, Derek Fine¹⁷, Jose Monroy-Trujillo¹⁷, H Michael Belmont⁷, William Apruzzese¹⁸, Anne Davidson¹⁹, Richard Furie²⁰, Paul Hoover²¹, Celine Berthier²², Maria Dall'Era²³, Diane Kamen²⁴, Kenneth Kalunian²⁵, Jennifer Anolik²⁶, Jennifer Barnas²⁷, Arnon Arazi²⁸, Soumya Raychaudhuri²⁹, Nir Hacohen³⁰, Robert Clancy³¹, Kelly Ruggles³², Michelle Petri³³ and Jill Buyon², and the Accelerating Medicines Partnership in RA/SLE, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴New York School of Medicine, Ann Arbor, MI, ⁵Harvard Medical School, Boston, MA, ⁶Michigan University, Ann Arbor, MI, ⁷NYU School of Medicine, New York, NY, ⁸Jacobs School of Medicine, University at Buffalo, Buffalo, NY, ⁹New York University Grossman School of Medicine, New York, NY, ¹⁰Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, ¹²University of California San Francisco, SF, CA, ¹³Northwell, New York, NY, ¹⁴Albert Einstein College of Medicine, Safed, Israel, ¹⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁶The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁷Johns Hopkins School of Medicine, Baltimore, MD, ¹⁸Brigham and Women's Hospital, Everett, MA, ¹⁹Feinstein Institutes for Medical Research, Manhasset, NY, ²⁰Northwell Health, Manhasset, NY, ²¹Brigham and Women's Hospital, SWAMPSCOTT, MA, ²²University of Michigan, Ann Arbor, MI, ²³UCSF, Corte Madera, CA, ²⁴Medical University of South Carolina, Charleston, SC, ²⁵University of California San Diego, La Jolla, CA, ²⁶University of Rochester Medical Center, Rochester, NY, ²⁷University of Rochester, Rochester, NY, ²⁸Feinstein Institutes for Medical Research, Melrose, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰Broad Institute of MIT and Harvard, Boston, MA, ³¹Columbia University Medical Center, New York, NY, ³²NYU Grossman School of Medicine, Brooklyn, NY, ³³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Detection of urinary CXCL6, a member of the IL-8 chemokine family, has been linked to CKD and is a proposed marker of chronic damage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].